404 related articles for article (PubMed ID: 12395219)
21. Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry's disease during enzyme-replacement therapy.
Prinz C; Farr M; Hering D; Horstkotte D; Faber L
Clin Res Cardiol; 2010 Jan; 99(1):53-5. PubMed ID: 19774328
[No Abstract] [Full Text] [Related]
22. New insights in cardiac structural changes in patients with Fabry's disease.
Linhart A; Palecek T; Bultas J; Ferguson JJ; Hrudová J; Karetová D; Zeman J; Ledvinová J; Poupetová H; Elleder M; Aschermann M
Am Heart J; 2000 Jun; 139(6):1101-8. PubMed ID: 10827394
[TBL] [Abstract][Full Text] [Related]
23. Fabry disease in cardiology practice: Literature review and expert point of view.
Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
[TBL] [Abstract][Full Text] [Related]
24. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
[TBL] [Abstract][Full Text] [Related]
26. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
Putko BN; Wen K; Thompson RB; Mullen J; Shanks M; Yogasundaram H; Sergi C; Oudit GY
Heart Fail Rev; 2015 Mar; 20(2):179-91. PubMed ID: 25030479
[TBL] [Abstract][Full Text] [Related]
27. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy.
Kubo T; Ochi Y; Baba Y; Hirota T; Tanioka K; Yamasaki N; Yoshimitsu M; Higuchi K; Takenaka T; Nakajima K; Togawa T; Tsukimura T; Sano S; Tei C; Sakuraba H; Kitaoka H
J Cardiol; 2017 Jan; 69(1):302-307. PubMed ID: 27554049
[TBL] [Abstract][Full Text] [Related]
29. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.
Sheppard MN; Cane P; Florio R; Kavantzas N; Close L; Shah J; Lee P; Elliott P
Cardiovasc Pathol; 2010; 19(5):293-301. PubMed ID: 19631563
[TBL] [Abstract][Full Text] [Related]
30. Fabry disease.
Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
[TBL] [Abstract][Full Text] [Related]
31. [Cardiac manifestations of Anderson-Fabry disease and efficacy of enzyme replacement therapy].
Hagège A
Rev Med Interne; 2010 Dec; 31 Suppl 2():S238-42. PubMed ID: 21211672
[TBL] [Abstract][Full Text] [Related]
32. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
33. Cardiac manifestations in Fabry disease.
Linhart A; Lubanda JC; Palecek T; Bultas J; Karetová D; Ledvinová J; Elleder M; Aschermann M
J Inherit Metab Dis; 2001; 24 Suppl 2():75-83; discussion 65. PubMed ID: 11758683
[TBL] [Abstract][Full Text] [Related]
34. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
35. Cardiac involvement in Anderson-Fabry disease.
Cauti FM; O'Mahony C; Pantazis A
BMJ Case Rep; 2010 Aug; 2010():. PubMed ID: 22767366
[TBL] [Abstract][Full Text] [Related]
36. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype.
San Román-Monserrat I; Moreno-Flores V; López-Cuenca D; Rodríguez-González-Herrero E; Guillén-Navarro E; Rodríguez-González-Herrero B; Alegría-Fernández M; Poza-Cisneros G; Piñero-Fernández JA; Sornichero-Martínez J; Gimeno-Blanes JR
Med Clin (Barc); 2014 Jun; 142(11):497-504. PubMed ID: 24679964
[TBL] [Abstract][Full Text] [Related]
38. Early detection of Fabry cardiomyopathy by tissue Doppler imaging.
Pieroni M; Chimenti C; Ricci R; Sale P; Russo MA; Frustaci A
Circulation; 2003 Apr; 107(15):1978-84. PubMed ID: 12668521
[TBL] [Abstract][Full Text] [Related]
39. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
[TBL] [Abstract][Full Text] [Related]
40. Cardiac involvement in Fabry disease.
Linhart A; Magage S; Palecek T; Bultas J
Acta Paediatr Suppl; 2002; 91(439):15-20. PubMed ID: 12572837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
